NCCN Guidelines® Insights: Breast Cancer, Version 4.2021
| العنوان: | NCCN Guidelines® Insights: Breast Cancer, Version 4.2021 |
|---|---|
| المؤلفون: | Joanne E. Mortimer, Mary Lou Smith, Rashmi Kumar, Karen L. Smith, Jame Abraham, Harold J. Burstein, Chau T. Dang, Doreen M. Agnese, Sharon H. Giordano, Lori J. Goldstein, Sara H. Javid, Sarah L. Blair, Jessica Young, Marilyn Leitch, Ingrid A. Mayer, Lori J. Pierce, Janice A. Lyons, Jairam Krishnamurthy, Kari B. Wisinski, John H. Ward, William J. Gradishar, Jennifer M. Matro, Matthew P. Goetz, Sameer A. Patel, Meena S. Moran, Erica Stringer-Reasor, Steven J. Isakoff, Ruth O'Regan, Jennifer L. Burns, Rebecca Aft, Hope S. Rugo, Melinda L. Telli, Anthony D. Elias, Rachel C. Jankowitz, Amy M. Sitapati, Kimberly H. Allison, Hatem Soliman, Sara A. Hurvitz |
| المصدر: | Journal of the National Comprehensive Cancer Network. 19:484-493 |
| بيانات النشر: | Harborside Press, LLC, 2021. |
| سنة النشر: | 2021 |
| مصطلحات موضوعية: | 0301 basic medicine, Oncology, medicine.medical_specialty, business.industry, Carcinoma in situ, Phyllodes tumor, medicine.disease, Inflammatory breast cancer, Systemic therapy, Patient advocacy, 03 medical and health sciences, 030104 developmental biology, 0302 clinical medicine, Breast cancer, Surgical oncology, 030220 oncology & carcinogenesis, Internal medicine, Male breast cancer, medicine, skin and connective tissue diseases, business |
| الوصف: | The NCCN Guidelines for Breast Cancer include up-to-date guidelines for clinical management of patients with carcinoma in situ, invasive breast cancer, Paget disease, phyllodes tumor, inflammatory breast cancer, male breast cancer, and breast cancer during pregnancy. These guidelines are developed by a multidisciplinary panel of representatives from NCCN Member Institutions with breast cancer–focused expertise in the fields of medical oncology, surgical oncology, radiation oncology, pathology, reconstructive surgery, and patient advocacy. These NCCN Guidelines Insights focus on the most recent updates to recommendations for adjuvant systemic therapy in patients with nonmetastatic, early-stage, hormone receptor–positive, HER2-negative breast cancer. |
| تدمد: | 1540-1413 1540-1405 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_________::221ae6dc6c853304470afa00fc246d15 https://doi.org/10.6004/jnccn.2021.0023 |
| حقوق: | OPEN |
| رقم الأكسشن: | edsair.doi...........221ae6dc6c853304470afa00fc246d15 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 15401413 15401405 |
|---|